COCarlos Vargas Oliva

Carlos Vargas Oliva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlos Vargas Oliva has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Asociación de la No Adherencia al Tratamiento en Pacientes con Hipertensión Arterial Sistémica y el Deterioro Cognitivo en Adultos Mayores de 65 Años

    by David Antonio Ramírez Pérez, Gisela Berenice Orozco Torres, Dulce María Román Romero, Marco Alejandro Nezahualcóyotl León Cardoso, Carlos Vargas Oliva

    Background. Aging population has increased the prevalence of chronic diseases such as systemic arterial hypertension (SAH), especially in older adults. One of the main challenges in its management is achieving adequate adherence to treatment, with various factors involved, including cognitive impairment. This condition affects functions such as memory, judgment, and comprehension, negatively impacting the patient's ability to follow therapeutic instructions. Given this context, it is considered important to analyze whether there is a relationship between non-adherence and cognitive impairment. Objective. To establish the association between non-adherence to antihypertensive treatment and cognitive impairment in adults over 65 years of age. Materials and methods. An analytical cross-sectional study was conducted in 193 hypertensive patients over 65 years of age. A non-probabilistic convenience sampling method was used. Adherence was assessed using the 8-item Morisky scale (MMAS-8), and cognitive status was assessed using the Mini-Mental State Examination (MMSE). Descriptive statistics and bivariate analysis using the Chi-square test (p<0.05) were applied. Results: 49.7% of patients were non-adherent to treatment. Among them, 30% presented cognitive impairment, compared to 14% in the adherent group (p=0.006). The prevalence of comorbidities was high, with diabetes mellitus (36.6%) and dyslipidemia (6.7%) being the most prominent. Conclusion: A statistically significant association was identified between non-adherence to treatment and cognitive impairment. These findings support the need to incorporate cognitive screening into the care of hypertensive older adults to improve adherence and clinical outcomes.

  • Open Access

    Perfil Clínico Epidemiológico de los Pacientes con Cáncer de Próstata Adscritos a la UMF N° 47 en el Periodo del 2019 a 2023

    by Mario Alberto Zuñiga Rios, Rubén Darío Arizola García, Gisela Berenice Orozco Torres, Carlos Vargas Oliva

    The study aimed to determine the clinical-epidemiological profile of patients with prostate cancer assigned to Family Medicine Unit No. 47 during the 2019–2023 period. It sought to describe their clinical characteristics, associated factors, and diagnostic patterns to generate information that contributes to improving timely detection and management of this disease. Prostate cancer is the second leading cause of cancer-related death in men worldwide and nationally. In Mexico, it maintains a high incidence, highlighting the importance of early detection as a strategy to intervene in initial stages and improve prognosis. The study used a quantitative approach with an observational, retrospective, cross-sectional, and descriptive design. Records from 159 confirmed patients were reviewed, analyzing sociodemographic, clinical, and diagnostic variables through descriptive statistics. The average age was 75.2 years, with most patients being retired men and having normal weight. Hypertension was the most frequent comorbidity. Prostate-specific antigen was the most commonly used diagnostic study, while urinary urgency was the most common symptom. The results emphasized the need to strengthen screening programs for men over 50 years of age and those with risk factors. They also highlighted the importance of promoting health education, reducing stigma, and encouraging a comprehensive approach that improves prognosis and quality of life.

  • Adult People with Hemophilia A Have Low Annualized Bleeding Rate, However the Arthropathy Remains a Burden: A Retrospective Cohort Study

    by Eréndira Pacheco Zavala, Carlos Vargas Oliva, Karla Edith Santibañez Bedolla, Blanca Olivia Murillo Ortíz, Octavio Martínez Villegas, Lauro Fabián Amador Medina

    Congenital Hemophilia A is a complex disease to treat, especially in places without access to hemophilia treatment centers (HTCs). The primary aim of this study was to analyze the outcomes of a cohort of adult people with congenital hemophilia A in an HTC localized in the Bajio region of Mexico. Observational retrospective study of a cohort of 82 adult people with congenital hemophilia A treated in a tertiary-level hospital in the Bajio region of Mexico, between June 2022 and June 2023. The median age of the patients was 29.5 years, 60.9% with severe hemophilia A, 53.6% were under some factor VIII prophylaxis regimen, and 52.4% had home therapy. The median annualized bleeding rate (ABR) was one bleed/year (IQR 0–3 bleeds/year) including a median of zero joint bleeds/year (IQR 0–3 bleeds/year). The presence of high-response inhibitors was detected in 8.5%, with an overall incidence of inhibitors of 14.6% of the cohort. Univariate analysis showed that inhibitors (OR 21.10; CI 95% 1.20–370.3; P = 0.03) and clinical arthropathy (OR 6.14; CI 95% 2.13–17.68; P = 0.001) were significantly higher in severe hemophilia. Clinically significant arthropathy was found in 71.9% of patients. Ultrasonography of the target joints showed that mainly cartilage degeneration was affected. Blood transfusion-associated viral infections were detected in 10.9% of patients. In our HTC, current treatment with hemostatic agents allows adequate control of ABR with acceptable inhibitor rates. However, we still have joint damage in most patients, which is partly explained by the fact that prophylaxis was introduced only in recent years.